Treatment of Guillain-Barré Syndrome with IVIG

First-Line Treatment Protocol

The American College of Physicians recommends intravenous immunoglobulin (IVIG) at 0.4 g/kg/day for 5 consecutive days as the first-line treatment for GBS patients with significant disability, and it should be initiated as early as possible, preferably within 2 weeks of symptom onset 1, 2
IVIG is preferred over plasma exchange as first-line therapy because it is easier to administer, more widely available, has higher completion rates, and causes fewer adverse effects, despite being more expensive 1

The standard dose of IVIG is 0.4 g/kg body weight daily for 5 consecutive days, with a total cumulative dose of 2 g/kg 1, 2, 3
Treatment should be initiated within 2 weeks of symptom onset for optimal efficacy 1
IVIG treatment is indicated in patients with GBS disability score ≥3 (unable to walk unaided) 1

In children, IVIG is strongly preferred over plasma exchange due to better tolerability and fewer complications, with a dose of 0.4 g/kg/day × 5 days 1, 2
For immune checkpoint inhibitor-related GBS, corticosteroids are recommended as first-line treatment, with IVIG or plasma exchange considered for severe cases 3, 4
In pregnant women, IVIG is preferred over plasma exchange due to fewer monitoring requirements 2

Approximately 20% of GBS patients require mechanical ventilation, and the "20/30/40 rule" should be used to assess respiratory failure risk, including vital capacity <20 ml/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O 1, 2

Certain medications, such as β-blockers, aminoglycosides, IV magnesium, fluoroquinolones, and macrolides, should be avoided as they worsen neuromuscular function 1, 2, 3

Aggressive management of complications is mandatory, including pain management with gabapentin, pregabalin, or duloxetine, DVT prophylaxis, pressure ulcer prevention, constipation/ileus management, and prevention of hospital-acquired infections 1, 2, 3

80% of patients regain walking ability at 6 months, with a mortality rate of 3-10% primarily due to cardiovascular and respiratory complications, and risk factors for poor outcome include advanced age, severe disease at onset, and lack of ICU support when needed 1, 2